The α2-adrenergic receptor agonist dexmedetomidine (DEX) exerts context-dependent antitumor effects, with its efficacy influenced by dose, immune cell involvement and combination with immune checkpoint inhibitors. It will be important to understand to which extent DEX and other α2-adrenergic agonists act on α2-adrenergic receptors from cancer and immune cells.
Liwei Zhao, Peng Liu, Allan Sauvat, Killian Carnet Le Provost, Jiani Liu, Andrea Checcoli, Jonathan Pol, Oliver Kepp, Guido Guido Kroemer, Lucillia Bezu
Natalie K. Wolf, Cristina Blaj, Lora K. Picton, Gail Snyder, Li Zhang, Christopher J. Nicolai, Chudi Ndubaku, Sarah M. McWhirter, K. Christopher García, David H Raulet
Discussion(0)
No comments yet. Be the first to comment.